International Journal of Colorectal Disease

, Volume 22, Issue 7, pp 833–839 | Cite as

Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis

  • M. RaithelEmail author
  • S. Winterkamp
  • M. Weidenhiller
  • S. Müller
  • E. G. Hahn
Case Report


Corticosteroids and 5-aminosalicylic acid are the primary standard therapy for inflammatory bowel disease. Recent immunologic data implicate an involvement of mast cell activation followed by increased histamine secretion and elevated tissue concentrations of histamine in the pathogenesis of ulcerative colitis. In the present case, the clinical course of a 35-year-old man with steroid-dependent chronic active ulcerative colitis, who did not respond to high-dose steroids, antibiotics, or azathioprine during 3 years, is reported. Clinical disease activity and established serological markers were recorded during 6 weeks of unsuccessful therapy and during the next 6 weeks, as a new nonsedative antihistaminergic drug, a mast cell stabilizer, and an hypoallergenic diet were implemented in addition to conventional therapy. Induction of remission was achieved within 2 weeks after treatment with fexofenadine, disodium cromoglycate, and an amino acid-based formula. Clinical disease activity, stool frequency, leukocytes, c-reactive protein, and orosomucoid levels in serum decreased rapidly. Daily steroid administration could be gradually reduced along with 6 weeks of this treatment. This report suggests that histamine and mast cell activity may be important pathophysiological factors responsible for persistent clinical and mucosal inflammatory activity in ulcerative colitis despite the use of steroids. In ulcerative colitis, patients unresponsive to conventional treatment, therapeutic considerations should also include an antiallergic approach when further signs of atopy or intestinal hypersensitivity are present.


Ulcerative colitis Steroid dependency Mast cells Antihistamines 


  1. 1.
    Rugtveit J, Nilsen EM, Bakka A et al (1997) Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112:1493–1505PubMedCrossRefGoogle Scholar
  2. 2.
    Raab Y, Sundberg Ch, Hällgren R et al (1995) Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol 90:614–620PubMedGoogle Scholar
  3. 3.
    Greenwald BD, James St P (1997) Immunology of inflammatory bowel disease. Curr Opin Gastroenterol 13:293–301CrossRefGoogle Scholar
  4. 4.
    Montelone G, Biancone L, Marasco R et al (1997) Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169–1178CrossRefGoogle Scholar
  5. 5.
    Cominelli F, Kam L (1993) Inflammatory mediators of inflammatory bowel disease. Curr Opin Gastroenterol 9:534–539Google Scholar
  6. 6.
    Roberts WG, Simon ThJ, Berlin RG et al (1997) Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK 591. Gastroenterology 112:725–732PubMedCrossRefGoogle Scholar
  7. 7.
    Stack WA, Jenkins D, Vivet P et al (1998) for the Platelet activating factor Antagonist Study Group in Ulcerative colitis: lack of effectiveness of the platelet-activating factor antagonist SR 27417A in patients with active ulcerative colitis: a randomized controlled trial. Gastroenterology 115:1340–1345PubMedCrossRefGoogle Scholar
  8. 8.
    Tromm A, Hüppe D, Eckenburg K et al (1993) Laboratory tests and activity indices in acute ulcerative colitis with respect to the extent of disease. Eur J Gastroenterol Hepatol 5:21–25Google Scholar
  9. 9.
    Heatley RV, Calcraft BJ, Rhodes J et al (1975) Disodium cromoglycate in the treatment of chronic proctitis. Gut 16:559–563PubMedGoogle Scholar
  10. 10.
    Mani V (1976) Treatment of ulcerative colitis with oral disodium cromoglycate. A double blind controlled trial. Lancet 1:439PubMedCrossRefGoogle Scholar
  11. 11.
    Malolepszy J (1977) Treatment of ulcerative colitis with disodium cromoglycate. Acta Allergol 32:82Google Scholar
  12. 12.
    Gould SR, Buckell NA, Day DW et al (1978) Controlled trial of disodium cromoglycate in chronic persistent colitis. Gut 19:1140–1143PubMedGoogle Scholar
  13. 13.
    Pugh SM (1979) Atopic disease in ulcerative colitis and Crohn’s disease. Clin Allergy 9:221PubMedCrossRefGoogle Scholar
  14. 14.
    Babb RR (1980) Cromolyn sodium in the treatment of ulcerative colitis. J Clin Gastroenterol 2:229PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenkrans PCM, Meijer CLJM, Van der Wal AM et al (1980) Allergic proctitis, a clinical and immunopathological entity. Gut 21:1017–1023Google Scholar
  16. 16.
    Whorwell PJ, Whorwell GN, Bamforth J et al (1981) A double-blind controlled trial of the effect of sodium cromoglycate in preventing relapse in ulcerative colitis. Postgrad Med J 57:436–438PubMedCrossRefGoogle Scholar
  17. 17.
    Odze RD, Wershil BK, Leichtner AM et al (1995) Allergic colitis in infants. J Pediatr 126:163–170PubMedCrossRefGoogle Scholar
  18. 18.
    Truelove SC (1961) Ulcerative colitis provoked by milk. Br Med J I:154–155CrossRefGoogle Scholar
  19. 19.
    Senju M (1988) Reaginic hypersensitivity in ulcerative colitis. Jpn J Gastroenterol 85:2168–2177 (in Jpn)Google Scholar
  20. 20.
    Jewell DB, Truelove SC (1972) Reaginic hypersensitivity in ulcerative colitis. Gut 13:903–906PubMedGoogle Scholar
  21. 21.
    Catlett JB (1988) Ulcerative colitis in an allergic person: case report. Va Med 115:434–435PubMedGoogle Scholar
  22. 22.
    Hanauer SB (1993) Medical therapy of ulcerative colitis. Lancet 342:412–417PubMedCrossRefGoogle Scholar
  23. 23.
    Hawthorne AB, Hawkey CJ (1989) Immunsuppressive drugs in inflammatory bowel disease: a review of their mechanisms of efficacy and place in therapy. Drugs 38:267–288PubMedCrossRefGoogle Scholar
  24. 24.
    Hanauer St B (1996) Inflammatory bowel disease. N Engl J Med 334:841–848PubMedCrossRefGoogle Scholar
  25. 25.
    Turunen UM, Farkkila MA, Hakala K et al (1998) Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 115:1072–1078PubMedCrossRefGoogle Scholar
  26. 26.
    Ooi ChJ, Sands BE (1999) Treatment of ulcerative colitis. Curr Opin Gastroenterol 15:298–301PubMedCrossRefGoogle Scholar
  27. 27.
    Abdelaziz MM, Devalia JL, Khair OA et al (1998) Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 101:410–420PubMedCrossRefGoogle Scholar
  28. 28.
    Raithel M, Matek M, Baenkler HW et al (1995) Mucosal histamine content and histamine secretion in Crohn’s disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 108:127–133PubMedCrossRefGoogle Scholar
  29. 29.
    Raithel M, Schneider Th, Hahn EG (1999) Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol 34:496–503PubMedCrossRefGoogle Scholar
  30. 30.
    Fellermann K, Ludwig D, Stahl M et al (1998) Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK 506). Am J Gastroenterol 93(10):1860–1866PubMedCrossRefGoogle Scholar
  31. 31.
    Kozarek RA, Patterson DJ, Gelfand MD et al (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110:353–356PubMedGoogle Scholar
  32. 32.
    Oren R, Arber N, Odes S et al (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110:1416–1421PubMedCrossRefGoogle Scholar
  33. 33.
    Ortolani C, Pastorello E, Zanussi C (1983) Prophylaxis of adverse reactrions to foods: a double-blind study of oral sodium cromoglycate for the prophylaxis of adverse reactions to foods and additives. Ann Allergy 50:105–109PubMedGoogle Scholar
  34. 34.
    Andre´ F, Andre´ C, Colin L et al (1995) IgE in stool as indicator of food sensitization. Allergy 50:328–333PubMedCrossRefGoogle Scholar
  35. 35.
    Jones NL, Roifman CM, Griffiths AM et al (1998) Ketotifen therapy for acute ulcerative colitis in children: a pilot study. Dig Dis Sci 43(3):609–615PubMedCrossRefGoogle Scholar
  36. 36.
    Smith TJ, Weis JH (1996) Mucosal T cells and mast cells share common adhesion receptors. Immunol Today 17:560–564Google Scholar
  37. 37.
    Raithel M, Weidenhiller M, Winterkamp S et al (1999) Is inflammatory bowel disease (IBD) always an idiopathic condition ? Identification of IBD patients with hypersensitivity to specific antigens. Gastroenterology 116(No. 4):G 3475Google Scholar
  38. 38.
    Fiocchi C (1990) Immune events associated with inflammatory bowel disease. Scand J Gastroenterol 25(Suppl 172):4–12Google Scholar
  39. 39.
    Iizuka M (1990) IgG subclass-containing cells in the human large bowel of normal controls, non-IBD colitis, and ulcerative colitis. Gastroenterol Jpn 25:24–31PubMedGoogle Scholar
  40. 40.
    Balazs M, Illyes G, Vadasz G (1989) Mast cells in ulcerative colitis. Quantitative and ultrastructural studies. Virchows Arch B Pathol 57:353–360CrossRefGoogle Scholar
  41. 41.
    Marshall JS, Bienenstock J (1990) Mast cells. Springer Semin Immunopathol 12:191–202PubMedCrossRefGoogle Scholar
  42. 42.
    Crowe SE, Luthra GK, Perdue MH (1997) Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease. Gut 41:785–792PubMedCrossRefGoogle Scholar
  43. 43.
    Stenton GR, Vliagoftis H, Befus D (1998) Role of intestinal mast cells in modulating gastrointestinal pathopyhsiology. Ann Allergy Asthma Immunol 81:1–15PubMedCrossRefGoogle Scholar
  44. 44.
    Galli St J, Maurer M, Lantz ChS (1999) Mast cells as sentinels of innate immunity. Curr Opin Immunol 11:53–59CrossRefGoogle Scholar
  45. 45.
    Collins SM (1996) Similarities and dissimilarities between asthma and inflammatory bowel disease. Aliment Pharmacol Ther 10(Suppl. 2):25–31PubMedGoogle Scholar
  46. 46.
    Simons FER (1997) Antihistamines. In: Kaplan AP (ed) Allergy, 2nd edn. WB Saunders, Philadelphia, pp 679–692Google Scholar
  47. 47.
    Glassmann MS, Newmann LJ, Berezin S et al (1990) Cow’s milk sensitivity during infancy in patients with inflammatory bowel disease. Am J Gastroenterol 85:838–840Google Scholar
  48. 48.
    Aiuti F, Paganelli R (1983) Food allergy and gastrointestinal diseases. Ann Allergy 51:275–280PubMedGoogle Scholar
  49. 49.
    Sampson HA (1997) Food allergy. JAMA 278:1888–1894PubMedCrossRefGoogle Scholar
  50. 50.
    Mishkin S (1997) Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Am J Clin Nutr 65:564–567PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. Raithel
    • 1
    Email author
  • S. Winterkamp
    • 1
  • M. Weidenhiller
    • 2
  • S. Müller
    • 3
  • E. G. Hahn
    • 1
  1. 1.Functional Tissue Diagnostics, Department of Medicine IUniversity Erlangen-NurembergErlangenGermany
  2. 2.Med. Clinics IIIKlinikum AugsburgAugsburgGermany
  3. 3.Department of PathologyUniversity ErlangenErlangenGermany

Personalised recommendations